Item 7.01 Regulation FD Disclosure.
On November 16, 2026, CG Oncology, Inc. (the “Company”) issued a press release entitled “PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC).” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
On November 16, 2026, the Company posted an updated corporate presentation on the Company’s website. A copy of this presentation is being furnished as Exhibit 99.2 to this Current Report on Form 8-K. Investors may also access the presentation by visiting the “Investor Relations” section of the Company’s website at www.cgoncology.com. The Company plans to use its website to disseminate future updates to its corporate presentation and does not intend to file or furnish a Form 8-K alerting investors each time the presentation is updated.
The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission (the “SEC”) made by the Company, regardless of any general incorporation language in such filing.
By furnishing the information in this Item 7.01, including Exhibits 99.1 and 99.2, the Company makes no admission as to the materiality of Item 7.01 in this report. The information contained in the corporate presentation is summary information that is intended to be considered in the context of the Company’s filings with the SEC and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Item 7.01, including Exhibits 99.1 and 99.2, although it may do so from time to time as its management believes is appropriate or as required by applicable law. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, by updating its website or through other public disclosure.
Item 8.01 Other Events.
On November 16, 2026, the Company announced topline data for its Phase 3 PIVOT-006 registrational trial evaluating adjuvant intravesical cretostimogene in patients with intermediate-risk and high-grade Ta ≤3 cm non-muscle invasive bladder cancer (“NMIBC”) following complete tumor resection. There are currently no U.S. Food and Drug Administration (“FDA”) approved adjuvant treatment options in this population of approximately 50,000 patients.
PIVOT-006 achieved its primary endpoint, demonstrating statistically significant and clinically meaningful improvements versus the control arm. Cretostimogene resulted in a 68% reduction in the risk of recurrence compared with the control arm, demonstrating a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001). The median follow-up was 17 months as of the October 26, 2026. Cretostimogene was generally well tolerated, with safety results consistent with those reported in previous studies. There were no Grade 3 or greater treatment-related adverse events ("TRAEs"), and no treatment-related discontinuations.
Additionally, the Company announced updated timing for the submission and completion of its current and planned biologics license applications (“BLAs”) with the FDA. The Company anticipates completing the submission of its BLA for the use of cretostimogene to treat patients with BCG-unresponsive NMIBC with carcinoma in situ ("CIS") with or without papillary tumors, which will now also include BCG-unresponsive high-grade papillary-only disease (without CIS), in March 2027. The Company also plans to submit a BLA for the use of cretostimogene in intermediate-risk and high-grade Ta NMIBC in the second quarter of 2027.
Forward Looking Statements
The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to: the significant improvement in recurrence-free survival observed in the PIVOT-006 registrational trial, the potential therapeutic benefits of cretostimogene for high-risk and intermediate-risk NMIBC patients, the planned timelines of the Company’s BLA submissions and their respective indications, the Company’s goal of securing the broadest possible label and including the totality of the BCG-unresponsive population at launch, cretostimogene’s potential as a backbone immunotherapy across the NMIBC spectrum, the potential of PIVOT-006 results to change clinical practice and broaden the patient populations that could benefit from cretostimogene, and the expected patient population size that could benefit from cretostimogene, if approved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation: topline data is based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial, and the FDA may not agree with the Company’s interpretation of such results; potential delays in the commencement, enrollment and completion of clinical trials; potential delays in the preparation, submission, acceptance, completion or review of the Company’s current and planned BLAs; the risk that regulatory authorities may require additional data or studies, may not approve cretostimogene, or may grant a narrower indication or label than anticipated; uncertainties regarding the timing and scope of any commercial launch and the Company’s ability to achieve anticipated patient access, market acceptance and therapeutic benefits; the risk that the target patient population size may be smaller than initially anticipated; the Company may use its capital resources sooner than expected and they may be insufficient to allow us to achieve the Company’s anticipated milestones; the Company’s dependence on third parties in connection with manufacturing, shipping and clinical and preclinical testing; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; and other risks described in the Company’s filings with the SEC, including under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K and other filings that the Company makes with the SEC from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Attacking Bladder Cancer for a Better Tomorrow Exhibit 99.2

Disclaimer and Forward-Looking Statements We caution you that this presentation contains forward-looking statements about us and our industry. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned clinical trials and preclinical studies for cretostimogene and any future product candidates, the timing and likelihood of regulatory filings and approvals for cretostimogene and any future product candidates, our ability to commercialize cretostimogene and any future product candidates, if approved, the potential that cretostimogine may be a best-in-disease product, if approved, the pricing and reimbursement of cretostimogene and any future product candidates, if approved, the potential to develop future product candidates, the potential benefits of strategic collaborations and potential to enter into any future strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: we currently depend entirely on the success of cretostimogene, which is our only product candidate and is based on a novel approach to the treatment of cancer; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unfavorable results from clinical trials; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; preliminary or interim data results are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and more patient data become available; our dependence on third parties in connection with manufacturing, shipping and clinical and preclinical testing; regulatory developments in the United States and foreign countries; our ability to obtain, maintain and enforce intellectual property protection for cretostimogene; we may use our capital resources sooner than we expect; we face significant competition who may develop products which are more effective, safer, or less expensive than our product candidate; and other risks described in our filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K, our quarterly Form 10-Q and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated. Cretostimogene grenadenorepvec is an investigational engineered oncolytic immunotherapy (OIT). It is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy has not been established. In BCG-unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC), cretostimogene has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination with other therapies in clinical trials. Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks and trade names referred to in this presentation appear without the ® and symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights to these trademarks and tradenames.

The Promise of Cretostimogene Potential Best-in-Disease Durability and Efficacy Results BOND-003 Cohort C (BCG UR CIS only)1: 76% CR anytime 46.4% (12-mo) 41.8% (24-mo) BOND-003 Cohort P (BCG UR Papillary only)2 95.7% (3-mo) HG-EFS 84.6% (6-mo) 80.4% (9-mo) CORE-008 Cohort A (BCG Naïve HR CIS)2 88% CR anytime PIVOT-006 (Intermediate-Risk + HG Ta)3 68% improvement in RFS with hazard ratio 0.32 (p<0.0001) Potential Best-in-Disease Safety/Tolerability Results4 Favorable safety & tolerable profile 0 Grade ≥ 3 TRAEs or deaths reported Most AEs were Grade 1‑2 Regulatory Status & Commercial Readiness Breakthrough Therapy & Fast Track designations Current capacity: 40-50k vials/year; 10x scale-up process to support future indications underway Commercial prep activities ongoing - MSLs/HSDs, site / payor engagement Administered like BCG, seamlessly integrating into established clinical workflows without re-training Physicians in top key accounts treat >70% of NMIBC patients by volume Dual MOA designed to selectively drive tumor killing & trigger durable anti-tumor immune response resulting in potential for best-in-disease profile across a broad range of NMIBC patients TRAEs = Treatment-related adverse events; HR = high-risk; NMIBC = Non-muscle invasive bladder cancer; MSL = Medical science liaison; HSD = Health system directors; MOA = Mechanism of action. 1. Ph 3 registrational study in HR BCG-unresponsive NMIBC CIS 2. Data presented at SUO Annual Meeting Dec. 2025, data as of September 1, 2025 3. From PIVOT-006 topline data announced Nov. 2026. 4. Observed in clinical trials of cretostimogene including BOND-003, CORE-008 and PIVOT-006

Comprehensive Programs in High-Risk and Intermediate-Risk NMIBC to Address a Multi-Billion Dollar Market Opportunity Cretostimogene Monotherapy Ph 1 Ph 2 Ph 3 Milestones / Status BCG-Unresponsive (BOND-003 Cohort C)1 Intermediate-Risk3 (PIVOT-006) BCG-Naïve High-Risk (CORE-008 Cohort A) BCG-Exposed High-Risk (CORE-008 Cohort B) 1 Patients with carcinoma in situ, with or without papillary disease. 2 Patients with papillary only. Cohort P is a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval. 3 Includes HG Ta ≤ 3cm Notes: Timing and achievement of milestone events are based on Company estimates and subject to risks and uncertainties. Actual results may be materially different than projected. Long-term Data Anticipated 2027 Topline Data Delivered 4Q’26 BCG-Unresponsive (CORE-001) Cretostimogene + Pembrolizumab 12-Month Data Anticipated 4Q’26 BCG-Unresponsive (BOND-003 Cohort P)2 Data Presented 4Q’25 Trial Initiated 2H’25 12-Month Data Anticipated 4Q’26 24-month Data Presented at 1H’24 BCG-Exposed High-Risk (CORE-008 Cohort CX) Cretostimogene + Gemcitabine Cretostimogene Combination Therapy

Cretostimogene’s Dual Mechanism of Action: Selective Tumor Killing Triggers Durable Anti-Tumor Immune Response Progeny viruses are released and enter new cancer cells Cretostimogene designed to stimulate cytokine and antigen release 1a 1b Attacking Bladder Cancer for a Better Tomorrow Cancer Cell Creto Progeny Tumor Antigens GM-CSF Cretostimogene designed to selectively replicate in and kill cancer cells 1 T-Cell Immune cells attack and kill additional cancer cells 2 Oncolytic Immunotherapy

Bladder wall Lamina Propria Inner Muscle Deep Muscle Inside of the bladder wall Outside of the bladder wall Carcinoma in Situ (CIS) Non-Invasive Papillary Carcinoma Tumor Invades Connective Tissue Tumor Invades Deep Muscle Tumor Invades Perivesical Tissue Tumor Invades Adjacent Tissue and Organs Tumor Invades Superficial Muscle CIS Ta T1 T2b T3 T4 T2a Muscle Invasive Bladder Cancer MIBC New bladder cancer cases for 60,892 new patients 20,297 new patients ~75% of Newly Diagnosed Bladder Cancer Cases are NMIBC ~25% of Newly Diagnosed Bladder Cancer Cases are MIBC Cancer of the Urinary Bladder - Cancer Stat Facts. SEER. Chang et al 2016. J Urol. 196:1021-1029. NMIBC Represents a Multi-Billion Dollar Market Opportunity in Bladder Cancer 6 Non-Muscle Invasive Bladder Cancer NMIBC

Patient Journey 2 Testing Work-up may include cystoscopy, urine cytology, and imaging (CT scan, MRI) 1 Symptoms Patient presents to primary care and/or urologist with symptoms (hematuria, urinary frequency) 3 TURBT1 TURBT, followed by tumor staging and grading Ongoing Treatment Require surveillance and/or treatment every 3 to 6 months for 2 to 5 years NMIBC Suspicion of Cancer 4 TURBT Low-Risk Perioperative Chemotherapy Note: Per NCCN guidelines, management of High-Risk NMIBC involves cystoscopy (Q3M for Year 1-2, Q6M for Year 3-5), upper tract imaging (baseline imaging and at Year 1, Q1-2Y for Year 3-5), abdomen/pelvis imaging (baseline imaging and as clinically indicated), and urine cytology (Q3M for Year 1-2, Q6M for Year 3-5). Biopsy is conducted during staging and for confirmation of disease when urine cytology is positive or presence of suspicious lesions. Intravesical BCG (Induction ± Maintenance) High-Risk Cystectomy *Quality of life implications Intravesical Chemotherapy Cystectomy Pembrolizumab, Nadofaragene, N-803 + BCG, TAR-200 TURBT Intermediate-Risk Intravesical BCG2 7 1 TURBT = Transurethral Resection of Bladder Tumor. 2 Due to BCG shortage, NCCN guidelines no longer recommend BCG therapy for Intermediate-Risk patients. Perioperative Chemotherapy

GAG Layer Tumor Standard Catheter Cretostimogene Cretostimogene is Intravesically Administered into the Bladder, Similar to Standard-of-Care BCG Therapy Which Urology Practices Perform Regularly BCG = Bacillus Calmette Guerin. DDM = n-Dodecyl β-D-maltoside. GAG = glycosaminoglycan. Procedure Can Be Prepared and Administered By: Medical Assistant, Nurse, Nurse Practitioner, Physician Assistant, or Urologist 8 DDM ~15 minutes Cretostimogene ~45 to 60 minutes

NMIBC (75%) Intermediate-Risk (30%) High-Risk (40%) BCG-Exposed BCG-Unresponsive BOND-003 Ph 3 Monotherapy Cohort C / Cohort P Cretostimogene Programs Across High-Risk & Intermediate-Risk NMIBC Potential to Address More Than 70% of NMIBC Market Note: CORE-001, CORE-008 Cohort B, and PIVOT-006 are in partnership with SUO-CTC. 1 CORE-008 is a multi-cohort study evaluating cretostimogene in High-Risk NMIBC. NMIBC = Non-muscle invasive bladder cancer CORE-0081 Cohort B PIVOT-006 Ph 3 Monotherapy CORE-0081 Cohort A CORE-0081 Cohort CX BCG-Naïve CORE-001 Ph 2 Checkpoint Combo 85K+ Bladder Cancer (U.S. Incidence) 730K+ Bladder Cancer (U.S. Prevalence) 75% NMIBC 9

Phase 3 Cretostimogene Monotherapy for BCG-Unresponsive NMIBC (NCT04452591) Cohort C DoR CR at 12 months PFS Additional Endpoints BCG-Unresponsive NMIBC Cretostimogene Single-Arm, Open-Label, Intravesical Administration CR at Any Time (CIS) EFS (Ta/T1) Study Design / Regimen Cohort C = BCG-unresponsive CIS with or without Ta/T1 (n=112) Induction course = Weekly x 6 (1 x 1012 vp) Second induction course1 = Weekly x 6 for non-responders Maintenance courses = Weekly x 3 for complete responders every 3 mos for first 12 mos, every 6 mos for next 24 mos Trial Design Pathologically confirmed BCG-Unresponsive CIS or HG Ta/T1 Have all Ta/T1 disease resected prior to treatment Trial designed to be compliant with 2018 FDA guidance Mandatory bladder mapping at 12-mos2 RFS = recurrence free survival. PFS = progression free survival. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years, as well as mandatory bladder mapping at month 12. 1 Second induction course of weekly x 6 for non-responders at month 3. 2 All patients required to undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR. Cohort P = BCG-unresponsive HG Ta/T1 without CIS (n=54) Same as Cohort C Cohort P RFS PFS BOND-003

BOND-003 Cohort C Overall Complete Response 75.5% (95% CI, 66.3% - 83.2%) CR (n=83) 25 Overall CR Rate (%) (n=110) 50 75 100 0 Efficacy data cutoff as of June 23, 2025. Efficacy analysis are centrally confirmed. All patients have active disease at baseline prior to enrollment. Received adequate BCG per FDA 2018 guidance. 1 Based on centrally confirmed responders who have reached 24-month evaluation timepoint. All 9 ongoing CRs remained in response at the 24-month assessment, as well as 3 additional patients confirmed to be in CR at Month 24 after further follow-up and central pathologic adjudication. 2 A CR is defined as having a negative cystoscopy, a negative urine cytology, and a negative biopsy. In addition, all patients at 12-month timepoint undergo mandatory, systematic bladder mapping of 5 locations, biopsy of the prostatic urethra, and upper tract imaging to confirm CR and detect potential occult disease in the bladder. 96.4% treated patients progression-free to MIBC at 24 months 81.2% cystectomy-free survival rate at Month 24 Among RCs, 83.3% (15/18) were T0 or NMIBC All complete responses have been centrally confirmed2 Cretostimogene Demonstrated Favorable Efficacy and Durability Data in NMIBC CR Landmark Analysis CR Rate, % (95% CI) CR by K-M Est, % (95% CI) 12-month 46.4% (36.8-56.2) 51/110 patients 50.7% (40.9, 59.8) 24-month 41.8% (32.5, 51.6)1 46/110 patients 42.4% (32.7-51.7%)

Cretostimogene Has Delivered Remarkable Complete Response (CR) Rate at 24 Months Cretostimogene demonstrated long-term DoR compared to approved drugs1 in NMIBC with 41.8% of patients in CR at 24 months 90% of patients in CR at 12 months maintained in CR at 24 months No grade 3+ TRAEs – favorable safety and tolerability results Cretostimogene Complete Response (CR) at 24-Month1 1. Compared to approved drugs with publicly available observed 24-Month CR data. From published data. (46/110) (19/77) (20/103) (9/96) Note: These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies.

1 These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies. From published data. 2 All 9 ongoing CRs remained in response at the 24-month assessment, as well as 3 additional patients confirmed to be in CR at Month 24 after further follow-up and central pathologic adjudication.. 3 CFS in responders. 4 Derived from ANKTIVA® plus BCG Package Insert (April 2024) using DOR ≥ 12 months and DOR ≥ 24 months to estimate 12 months and 24 months landmark CR rate. 5 ADSTILADRIN® Package Insert (December 2022) and Summary Basis for Regulatory Action. 6 Derived from GU ASCO 2021, Balar et al presentation DOR ≥ 24 months to estimate 24-months landmark CR. References: Merck: (FDA & ODAC presentation slides, NDA/BLA# 125514s-066 for pembrolizumab (https://www.fda.gov/media/133956/download), Balar, AB et al. Lancet Onc. Epub ahead of print. 2021 May 26.; 2021 ASCO GU presentation); FerGene: (Boorjian et al. Lancet Oncol. 2021 Jan;22(1):107-117. Epub 2020 Nov 27) (Narayan et al. Journal of Urology. April 2024 doi:10.1097/JU.0000000000004020). ImmunityBio (ANKTIVA® plus BCG Package Insert; FDA Approval Letter). Janssen (SunRISe-1 – ESMO 2024; Daneshmand et al, Journal of Clinical Oncology, July 24, 2025). CG Oncology (BOND-003 – SUO 2024 and NE AUA 2025; CORE-001 – ASCO 2024). Trial (Status) BOND-003 COHORT C (Ph3 Ongoing) SunRISe-1 (Approved) QUILT 3.032 (Approved) NCT02773849 (Approved) KEYNOTE-057 (Approved) Drug Cretostimogene TAR-200 N-803 + BCG Nadofaragene Pembrolizumab Mechanism Oncolytic Immunotherapy Gemcitabine via In-Dwelling Device IL-15 Superagonist + BCG combo Gene Therapy Secreting IFN Checkpoint Inhibitor RoA Intravesical Transurethral Procedure Intravesical Intravesical Intravenous Efficacy Population 110 83 77 98 96 CR at Any Time 75.5% (83/110) [95% CI: 66% - 83%] 82.4% (70/83) [95% CI: 73% - 90%] 62.3% (48/77) [95% CI: 51% - 73%] 51.0% (50/98)5 [95% CI: 41% - 61%] 40.6% (39/96) [95% CI: 31% - 51%] CR at 12 Mo 46.4% (51/110) [95% CI: 37% - 56%] K-M: 45.9% (39/83) 36.4% (28/77)4 24.3% (25/103) 18.8% (18/96) CR at 24 Mo 41.8% (46/110)2 [95% CI: 33% - 52%] Not Reported 24.7% (19/77)4 19.4% (20/103) 9.4% (9/96)6 12M DOR K-M: 64.2% [95% CI: 52% - 74%] Observed: 52.9% K-M: 56.2% 58% 46% 46% 24M DOR K-M: 60.1% [95% CI: 48% - 70%] K-M: 51.8% 40% Not Reported Not Reported Free from Progression to MIBC 96.4% at 24 month 94.3% 90% 94% 89% Cystectomy Free Survival 89.2% at 12 month 81.3% at 24 month3 86.6% at 12 month3 59%3 64% at 24-month 84% Median Time to AE Resolution 1 Day 3.1 weeks Not Reported Not Reported Not Reported Grade 3+ TRAE 0% 13% Not reported; 16% SAE 4% 13% TR discontinuation 0% 3.5% 7% 3% 11% CIS with or without Ta/T1 Cretostimogene is Well Positioned as Backbone Therapy in NMIBC with Potential Best-in-Disease Durability & Safety in BCG-UR 1

Creto High-Grade Event-Free Survival (HG-EFS) vs. DFS/RFS (by K-M)1 BOND-003 Cohort P reported 95.7%, 84.6% and 80.4% HG Event-Free Survival (EFS) at 3, 6 and 9 months, respectively No serious treatment-related adverse events (TRAEs) and no discontinuations related to cretostimogene No dose delays, missed doses due to TRAEs 0% Grade ≥ 3 TRAEs, Serious TRAE, deaths BOND-003 Cohort P BCG-Unresponsive Papillary (HG Ta/T1) Patients Compared to approved drugs with publicly available EFS by K-M From published data. Note: These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies.

Cretostimogene is Well Positioned in BCG-UR Papillary Only NMIBC with Potentially Best-in-Disease EFS Endpoint1 Papillary Only (HG Ta/T1) Trial (Status) BOND-003 COHORT P (Ph3 Ongoing)1 SunRISe-12 QUILT 3.0323 NCT027738494,5 KEYNOTE-0576 Drug Cretostimogene TAR-200 N-803 + BCG Nadofaragene Pembrolizumab Mechanism Oncolytic Immunotherapy Gemcitabine via In-Dwelling Device IL-15 Superagonist + BCG combo Gene Therapy Secreting IFN Checkpoint Inhibitor RoA Intravesical Transurethral Procedure Intravesical Intravesical Intravenous Efficacy Population N=54 N=52 N=72 N=50 N=132 EFS/DFS/HG-RFS 3 month 95.7 [95% CI: 83.8, 98.9] Not Reported 92.8% [95% CI]* 72.9 [95% CI: 58.2-84.7] 87.7 [95% CI: 80.7-92.3] 6 month 84.6 [95% CI: 68.6, 92.9] 85.3 [95% CI: 71.6-92.7] 75.9% [95% CI]* 62.5 [95% CI: 47.4-76.0] 53.1 [95% CI: 44.1-61.2] 9 month 80.4 [95% CI: 62.3, 90.4] 81.1 [95% CI: 66.7- 89.7] Not Reported 58.3 [95% CI: 43.2–72.4] Not Reported 12 month Not Yet Reached 70.2% [95% CI: 59.2-84.6] 55.4 [95% CI: 42.0-66.8] 43.8 [95% CI: 29.5-58.8] 43.5 [95% CI: 34.9-51.9] 24 month Not Yet Reached Not Reported 48.3 [95% CI: 34.5-60.7] 33.3 [95% CI: 20.4-48.4] 34.9 [95% CI: 26.4-43.4] Safety Grade 3+ TRAE 0 (0%) 13.5% Not Reported 4% 14% TR discontinuation 0 (0%) 7.7% 7% 3% 11% SAEs 0 (0%) 5.8% including sepsis, spinal fracture (procedure related), and UTI 16%** 11% 13% Note: These data are not based on head-to-head or comparator studies. Differences exist between study designs and subject characteristics, and caution should be exercised when comparing data across studies. 1. SUO 2025 Annual Meeting; 2. JCO - https://doi.org/10.1200/JCO-25-01651 Phase IIb SunRISe-1 study and SUO 2025 Annual Meeting presentation; 3. Chamie K, et al. NEJM Evid. 2023; 2(1):EVIDoa2200167 *estimated from subsequent landmark reports; **SAEs are combined across multiple cohorts as listed in package insert; 4. Boorjian S, et al. Lancet Oncology. 2021; 22(1):107-117. 5. Narayan VM, et al. J Urol. 2024;212(1):74-86; 6. Necchi A, et al. Lancet Oncology. 2024; 25(6):720-730. 15

Additional Endpoints Study Design / Regimen Population RFS at 12-month and 24-month PFS Safety Intermediate-Risk (IR) NMIBC (Enrollment Completed) Cretostimogene vs Surveillance/TURBT Randomized (1:1), Two Arms, Open-Label (n=367) Primary Endpoint: RFS Rate Arm A: Cretostimogene following TURBT Induction course = Weekly x 6 (1 x 1012 vp) Maintenance courses1 = Weekly x 3 (1 x 1012 vp) for complete responders Arm B: Surveillance following TURBT Patients with disease recurrence eligible to receive cretostimogene Pathologically confirmed IR per AUA/SUO Guidelines* Recurrent LG Ta < 12mo Solitary LG Ta > 3cm LG Ta multifocal Solitary HG Ta ≤ 3cm LG T1 All disease removed by TURBT at baseline RFS = recurrence free survival. PFS = progression free survival. *Guidelines at the time of enrollment and study start Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years; mandatory, site-directed biopsy at month 12. 1 Maintenance course for complete responders weekly x 3 at month 3 and month 6, and once every 3 months at month 9 and month 12. Ph 3 Adjuvant Cretostimogene for IR NMIBC, Enrollment Completed Ahead of Schedule in Broad Population of IR NMIBC Patients PIVOT-006

Cretostimogene (PIVOT-006) (investigational) TAR-210 (MoonRIse-1) (investigational) UGN-102 (Approved) IR NMIBC LG Newly Diagnosed IR NMIBC LG Recurrent HG Ta <3cm (solitary) Adjuvant (non-chemoablative) 50K2 Pts (US TAM) Intermediate-Risk Landscape PIVOT-006 Designed to Evaluate Cretostimogene in a Broad Patient Population Across Intermediate-Risk (IR) NMIBC 1. PIVOT-006 is the first Ph 3 randomized trial in this patient population, encompassing the broadest range of patient types per AUA/SUO Guidelines including HG Ta solitary lesions <3cm. 2. NIH SEER secondary claims data analytics, and management assumptions. 3. Indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) MoonRIse-1 Ph 3 Trial Study not designed to enroll: Solitary HG Ta <3cm FGFR wildtype PIVOT-006 Ph 3 Trial Study designed to enroll: All intermediate-risk patients First Ph 3 randomized trial in broad IR NMIBC population1 Prescribing Information3 Not indicated for: Solitary HG Ta <3cm Newly diagnosed LG = under development for indication = FDA approved indication

68% Improvement in RFS Hazard Ratio 95% CI 0.23–0.45 | p<0.0001 Cretostimogene Significantly Improved Recurrence-Free Survival (RFS) in Intermediate-Risk and HG Ta NMIBC PIVOT-006 The median follow-up was 17 months at the time of data cutoff Oct. 26,2026. Recurrence was dated to the first evaluable assessment documenting recurrence. Participants were censored at randomization if no evaluable post-randomization assessment was available; otherwise, censoring occurred at the last evaluable recurrence-free assessment for no recurrence, death, or recurrence/death following ≥1 missed or nonevaluable assessment, and before initiation of new anticancer therapy. Death was not considered an RFS event. CI, confidence interval; HG, high-grade; HR, hazard ratio; NMIBC, non-muscle invasive bladder cancer No Grade ≥3 treatment-related adverse events No treatment-related discontinuations PIVOT-006 topline results to be presented as a late-breaking podium presentation at SUO on December 2, 2026 PIVOT-006 data will support a second BLA submission in intermediate-risk and high-grade Ta NMIBC anticipated in Q2 2027 0.32

Ph 2 Cretostimogene in Combination for BCG-Exposed HR & BCG-Unresponsive NMIBC (Cohort CX) CORE-008 Cohort CX CR at any time CR at 12 months DoR PFS CFS Additional Endpoints HR BCG-Exposed & BCG Unresponsive NMIBC Study Design / Regimen Primary Endpoint: HG-EFS Cohort CX (CIS-containing or HG Ta/T1) Arm 1 = cretostimogene + gemcitabine (concurrent) Arm 2 = cretostimogene + gemcitabine (sequential) Standard weekly x 6 induction, reinduction and weekly x 3 maintenance until Year 31 Population Pathologically confirmed BCG-exposed HR & BCG-UR Persistent or recurrent HG Ta or CIS at first evaluation after adequate BCG dose HG recurrence outside of BCG-UR window within 24 mos after last adequate BCG dose HG recurrence within 24 mos after last inadequate BCG dose HR = high risk. HG = high grade. LG = low grade. DoR = duration of response. EFS = event free survival. RFS = recurrence free survival. PFS = progression free survival. CFS = cystectomy free survival. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years 1 Second induction course of weekly x 6 for non-responders at month 3. Maintenance course for complete responders weekly x 3 every 3 months in Year 1, and every 6 months in Year 2 and Year 3. Cretostimogene + Gemcitabine 1:1 Randomized, Two Arm, Open-Label

CORE-008 Cohort CX High-Grade Event-Free Survival at 3 and 6-Months (ITT Population) Median follow-up: 6.6 months No significant differences in HG-EFS by arm Consistent response among BCG-UR and BCG-exposed subgroups Arm 1 (Concurrent) Arm 2 (Sequential) Censored Overall Estimated HG-EFS at Month 3 96.0% (95% CI: 84.0 – 99.0) Estimated HG-EFS at Month 6 89.5% (95% CI: 76.6 – 95.5) BCG-UR= BCG-Unresponsive; CIS= Carcinoma in Situ; HG-EFS= High-Grade Event-Free Survival; MIBC= Muscle Invasive Bladder Cancer; mUC= Metastatic Urothelial Carcinoma; HG-EFS defined as high-grade recurrence/persistence, progression to T1, progression to T2+ and death from any cause; Efficacy data cutoff as of 13MAR2026; Efficacy assessments based on local pathology review; HG-EFS presented in intention to treat (ITT) population representative of all patients randomized on CORE-008 Cohort CX (Arm 1/Concurrent; Arm 2/Sequential); Two patients with CIS at baseline were found with HGT1 at Month 6.

CORE-008 Cohort CX High Complete Response Rates Observed Within CIS-Containing Population IVE gem 85.7% (95% CI, 67.3% – 96.0%) CR at Anytime (n=24) 25 (n=28) 50 75 100 0 92.3% (95% CI, 74.9% - 99.1%) CR at Anytime (n=24) Intention to Treat Population* Efficacy Evaluable Population** (n=26) Complete Response at Any Time (%) Includes BCG-Exposed and BCG-Unresponsive patients 0% Grade ≥ 3 TRAEs, SAEs or deaths 85.5% (47/55) completed all protocol-defined treatments Arm 1 (Concurrent)- 71.4% (20/28) Arm 2 (Sequential)- 100% (27/27) No patients discontinued on Arm 2 (sequential) due to TRAE 4 patients withdrew from Arm 1 (concurrent) for persistent grade 1-2 localized TRAEs No difference in the proportion of patients with AEs between arms CIS= Carcinoma in Situ; CR=Complete Response; CR defined as having negative cystoscopy, urine cytology, and biopsy (as indicated). Efficacy data cutoff as of 13MAR2026. Efficacy assessments based on local pathology review. * Intention to treatment (ITT) population includes all participants who are randomized in Cohort CX (Arm 1/Concurrent; Arm 2/Sequential). ** Efficacy evaluable population includes patients who have received at least four doses of cretostimogene, meet the definition of BCG-Unresponsive/BCG-Exposed and have completed a protocol-defined efficacy assessment at Month 3

Phase 2 Cretostimogene Monotherapy for BCG-Naïve High-Risk (HR) and BCG-Exposed HR NMIBC (Cohort A and B) CORE-008 Cohort A & B Cohort A DoR (in CIS) EFS, LG-RFS, CFS Cohort B DoR (in CIS) EFS, LG-RFS, CFS Additional Endpoints BCG-Naïve & BCG-Exposed (Actively Enrolling) Cretostimogene Two Cohorts (A and B), Two Arms Each, Open-Label Primary Endpoint: CR Rate; HG-EFS2 Study Design / Regimen Cohort A (BCG-naïve HR NMIBC) CIS ± HG Ta/T1 (n=~50) HG Ta/T1 only (n=~75) Standard weekly x 6 induction, reinduction and weekly x 3 maintenance until Year 31 Cohort B (BCG-exposed HR NMIBC) CIS ± HG Ta/T1 (n=~75) HG Ta/T1 only (n=~75) Standard dosing as above1 Population Cohort A Pathologically confirmed BCG-naïve HR NMIBC No prior treatment with BCG within past 24 months Cohort B Pathologically confirmed BCG-exposed HR NMIBC Recurrence within 24 months after last adequate BCG dose HR = high-risk. HG = high grade. LG = low grade. DoR = duration of response. EFS = event free survival. RFS = recurrence free survival. PFS = progression free survival. CFS = cystectomy free survival. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years; mandatory, site-directed biopsy at month 12. 1. Second induction course of weekly x 6 for non-responders at month 3. Maintenance course for complete responders weekly x 3 every 3 months in Year 1, and every 6 months in Year 2 and Year 3. 2. CIS (CR Rate) and HG Ta/T1 (HG-EFS)

High Initial Response Rates from CORE-008 Cohort A CORE-008 Cohort A (n=49*) Overall Complete Response 83.7% (95% CI, 70.33% - 92.7%) CR (n=41) 25 Overall CR Rate (%) (n=49)1 50 75 100 0 CR Landmark Analysis CR Rate, % (95% CI) Original Instillation2 (5-step) 79.2% (57.8, 92.9) 19 out of 24 patients Optimized Instillation3 (2-step) 88.0% (68.8, 97.5)1 22 out of 25 patients 0% Grade ≥ 3 TRAEs, SAEs or deaths No treatment related discontinuations No patients required radical cystectomy No treatment-related progression to MIBC or mUC Note: Efficacy data cutoff as of 01SEP2025. Efficacy analysis centrally confirmed. All patients have active disease at baseline prior to enrollment. A CR is defined as having a negative cystoscopy, a negative urine cytology, and a negative biopsy (as indicated). Analysis based on both landmark CR rate assessed in clinical trial and DoR by Kaplan-Meier estimate. 1 49 patients were assessed for efficacy at the time of data cutoff. 4 re-induced patients are pending 6-month assessments. 2 Original instillation included 5-step instillation with series of bladder saline washes followed by DDM and cretostimogene instillations. 3 Optimized instillation streamlined the process to 2-steps inclusive of DDM followed by cretostimogene instillations.

Advancing Cretostimogene to Optimized Instillation Optimized Instillation Cohort A data supports optimized instillation Potential meaningful benefit to patients and sites (esp. high-volume centers) with estimated ~20-minute time savings Administered via soft catheter by medical assistant, a urologist or MD does not have to be involved in process Seamless transition for BCG sites, seamless integration into established clinical workflows without re-training Closed System Drug Transfer Devices (CSTD) enables direct vial>syringe>bladder delivery All studies beyond BOND-003 Cohort C use optimized instillation protocol Original Process Five-Step Optimized Process Two-Step Step 1: Saline Wash Step 2: DDM Rinse Step 3: DDM Dwell Step 4: Saline Wash Step 1: DDM Dwell Step 2: Creto Dwell Step 5: Creto Dwell ~25% Time Savings | 3 Steps Eliminated | Improved Benefit to Site & Patient

Key Clinical Metrics Driving HCP Treatment Decisions in BCG-Unresponsive NMIBC* *Market Research across ~100 US HCPs (n=46 urologists, n=54 uro-oncologists), Survey was fielded Nov-Dec 2025 Chart represents percentages ranking as top 3 factors that drive treatment decisions

CG is Building a Capital-Efficient, High-Touch Approach in Anticipation of a Successful Launch Across a Concentrated Prescriber Network Field Organization Key Account Managers Health System Directors Regional Business Directors National Account Leads Medical Science Liaisons Field Reimbursement Managers Physicians Treating NMIBC Patients Community (LUGPA, Independent) | Academic (Health Systems, Federal, Comprehensive Care) Top decile (~10 network urology centers) alone account for ~10% of national volume Targeting Reaching Sites Prescribers <75 field team Community Academic Leading urology center network represent >70% of the market opportunity by volume

The Path to 150K+ Addressable Patients NMIBC = Non-muscle invasive bladder cancer; HR = high-risk; IR = Intermediate-risk + HG Ta ≤ 3cm TAM derived from NIH SEER, secondary claims data analytics, and management assumptions 150K+ Annualized WAC of approved therapies in HR NMIBC range from $200K to $690K 50K 50K 25K 25K BOND-003 Cohorts C & P PIVOT-006 CORE-008 Cohorts CX & B CORE-008 Cohort A

Catalyst Rich Calendar Through Potential First Approval and Launch Followed by Potential Frontline Bladder Indication Expansion Anticipated Milestones* BCG-UR = BCG-unresponsive. *Note: Timing and achievement of milestone events are based on Company estimates and subject to risks and uncertainties. Actual results may be materially different than projected. 1. BCG-unresponsive NMIBC indication expansion to now include high-grade papillary-only disease Program 2025 2026* 2027* High Risk (HR) NMIBC Intermediate Risk (IR) NMIBC Initiation of Cretostimogene BLA Submission BOND-003 Cohort C BCG-UR Long-Term Durability Data PIVOT-006 Enrollment Completed BOND-003 Cohort P BCG-UR Topline Data CORE-008 Cohort A BCG-Naive Data* Completion of BLA Submission BCG-UR (1st Indication)1 BOND-003 Cohort C BCG-UR Long-Term Data CORE-008 Cohort CX BCG-Exp. Topline Data (Creto + Gem) BOND-003 Cohort P BCG-UR Durability Data PIVOT-006 Topline Data Completion of BLA Submission (2nd Indication) Regulatory Clinical CORE-008 Cohort CX BCG-Exposed Durability Data CORE-008 Cohort A BCG-Naïve Durability Data Initiation of BCG-Exposed Ph 3 Trial

www.CGOncology.com CONTACT US GENERAL INQUIRIES Information@cgoncology.com MEDIA MediaRelations@cgoncology.com

Leadership with Deep Industry Experience with Track Record of Success in Drug Development and Commercialization Arthur Kuan Chairman, President & Chief Executive Officer 13 years of expertise within the NMIBC space 2020 Forbes 30 Under 30 featured honoree in healthcare Jim DeTore Chief Financial Officer 30+ years of life sciences expertise Raised over a billion dollars in equity capital Vijay Kasturi, M.D. Chief Medical Officer 25+ years as GU Medical Oncologist Managed launch plan for BAVENCIO® and FOTIVDA® Swapnil Bhargava, Ph.D. Chief Technical Officer Supported multiple INDs, BLAs, and modalities to the clinic and market (TIVDAK®, PADCEV®, and ADCETRIS®) Isabel Kalofonos Chief Commercial Officer 20+ years driving launches and commercial execution Led launches of ELAHERE®, PALSONIFY and TAKHZYRO® Josh Patterson, Esq. General Counsel & CCO 25 years as in-house counsel in biopharmaceutical industry Over $2.25B in transaction experience 30

Our Vision We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. Our Mission We are focused on developing bladder-sparing therapeutics for patients afflicted with bladder cancer. Attacking Bladder Cancer for a Better Tomorrow